It has been shown that nivolumab plus ipilimumab is cost-effective for patients suffered from cancer, such as advanced NSCLC with PD-L1 expression level <1%, PD-L1-positive advanced renal-cell carcinoma from the US payer's perspective (34, 36). This evidence concerns the gene CD274 and cancer.